Research programme: antimalarials - 4SC Discovery/University Hospital Heidelberg

Drug Profile

Research programme: antimalarials - 4SC Discovery/University Hospital Heidelberg

Latest Information Update: 25 Apr 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator 4SC Discovery
  • Developer 4SC Discovery; University Hospital Heidelberg
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Malaria

Most Recent Events

  • 20 Mar 2014 4SC Discovery and University Hospital Heidelburg agree to co-develop antimalarials for Malaria
  • 20 Mar 2014 Antimalarials developed from this research programme are available for licensing after preclinical development
  • 20 Mar 2014 Preclinical trials in Malaria in Germany (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top